The session Medical Ethics focuses on the role of the Clinical Pharmacologists in an Ethics committee. What is necessary training and experience for Clinical Pharmacologists to be able to function properly in an Ethics committee? What are the consequences of new European regulation. What is the exact role of the pharmacist in an Ethics committee in relation to the clinical pharmacologist. Is there need for a national training program for clinical pharmacologists who (will) function in an Ethics committee and what should be the content of this training program?
Receptor Pharmacology and Signal Transduction
The subject of the session which we organize in collaboration with the NVF and KNCV - section pharmacochemistry is Receptor Pharmacology and Signal Transduction
When and how a cell knows which signal is essential to adapt to changing environments? This question represents the basis of receptor pharmacology and signal transduction research. Our session includes research on understanding how a cell integrates sensing to signaling and transduces these signals from the plasma membrane to mitochondria, endoplasmic reticulum and to the nucleus. It consist of a complex series of intracellular cascades mediated by modulation of G-protein-coupled receptors, phospholipids, calcium, or protein phosphorylation. Understanding these processes might provide a detailed roadmap of how cells work, and ultimately of human physiology and pathologies. Therefore, this knowledge is essential for the development of novel therapeutic strategies to treat cancer, cardiovascular, neurological and metabolic disorders. These research questions fit well in the theme of the FIGON Drugs and Microbes, since it links the external signals to potential therapies against human diseases.
Prof. dr. Martine Smit is professor at the division of Medicinal Chemistry at the Vrije Universiteit Amsterdam. Her research focuses on unraveling and modulating (e.g. nanobodies) signaling networks activated by (oncogenic) G protein-coupled receptors, with a specific interest in (viral) chemokine receptors. She is chairing this session on behalf of the Dutch Pharmacological Society and section KNCV-Farmacochemie.
dr. Amalia Dolga is an Assistant Professor and a Rosalind Franklin Fellow at the University of Groningen, Department of Molecular Pharmacology, Groningen Research Institute of Pharmacy. Her lab investigates molecular mechanisms of neurodegeneration (Alzheimer's and Parkinson's disease), with a focus on potassium channel modulation, mitochondrial metabolism and inflammation. She is co-chairing this session on behalf of the Dutch Pharmaceutical Society."